On Monday, Baxter's shares initially fell as much as 4.1%, but later settled at a 2.3% decline, trading at $38.01 by midday in New York. Baxter’s stock ended up closing right below $38 a share Monday.

Read Also: Hurricane Helene Exposes Vulnerability Of Florida’s Home Insurance Market

Patrick Wood, an equity analyst at Morgan Stanley, covered the hurricane-related disruption in a note Monday, outlining the potential financial harm caused by the storm. Wood pointed to a 2017 hurricane, which impacted Baxter’s capacity in Puerto Rico, as a precedent for Hurricane Helene.

“To sense check, if we assumed a $140mn impact in BAX's Q4 (given Q3 is essentially over), that implies about 4 days worth of shutdown for the entire US Chronic Therapies and Infusion Therapies businesses,” Wood wrote in the note. “Though in reality more given this is unlikely the only facility where PD and IV solutions are produced and BAX can presumably shift capacity around.”

Baxter is working closely with local officials to bring the North Cove plant back online. Fortunately, none of the facility's 2,500 employees were injured. However, the company is still verifying the safety of its workforce as communication in the area has been hampered by outages in cellular service.

Keep Reading:
• Hurricane Helene Devastates Southeastern U.S., Slamming Infrastructure And Leaving Millions Powerless